Ikigai Global Industries Announces Breakthrough in Bioadaptive Skincare Technology

SINGAPORE — Ikigai Life Sciences today announced SAISEI, a bioadaptive skincare line built on adaptive peptide technology that responds to cellular fatigue in real time.

"Sleep is one method of restoration," said Dr. Ingrid Vasa-Watanabe, Chief Science Officer of Ikigai Life Sciences. "It is not the only method, and it is far from the most efficient. SAISEI restores the visible signature of rest to those whose nights are already spoken for."

In clinical evaluation, SAISEI users displaying the dermal markers of ninety-hour work weeks were assessed by independent observers as "well-rested" in ninety-six percent of cases. The line's flagship serum was developed in-house and tested extensively on volunteer employees, of whom, the company emphasizes, there was no shortage.

"Our people asked for this product," Dr. Vasa-Watanabe said. "Not to appear rested for its own sake, but because visible fatigue is a discourtesy to one's colleagues. Presentation is respect. That is the fourth tenet."

SAISEI reaches selected markets in the fourth quarter. The company anticipates supply constraints and has advised retail partners that employees of Ikigai Global Industries will be served first.

About Ikigai Global Industries
Founded in Tokyo in 1949, Ikigai Global Industries is a diversified enterprise operating across rail and infrastructure, energy systems, consumer technology, and life sciences in thirty-one countries. Its 118,000 employees are united by the Bushido Code, the company's founding tenets. Only exceptional people work here. Media contact: press@ikigaiglobalindustries.com